Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Human Gene Therapy

• Publication date

  2017-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hum.2017.004PMID 28530135PMCID PMC5549796
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transgene Expression in Dogs After Liver-Directed Hydrodynamic Delivery of Sleeping Beauty Transposons Using Balloon Catheters

  2017cited by this paper
• A Broad Range of Dose Optima Achieve High-level, Long-term Gene Expression After Hydrodynamic Delivery of Sleeping Beauty Transposons Using Hyperactive SB100x Transposase

  2016cited by this paper
• Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

  2016cited by this paper
• Human AAT gene transfer to pig liver improved by using a perfusion isolated organ endovascular procedure

  2015cited by this paper
• Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII

  2015cited by this paper
• Sleeping Beauty Transposition

  2015cited by this paper
• Enhanced Efficacy from Gene Therapy in Pompe Disease Using Coreceptor Blockade

  2015cited by this paper
• Continual Low-Dose Infusion of Sulfamidase Is Superior to Intermittent High-Dose Delivery in Ameliorating Neuropathology in the MPS IIIA Mouse Brain.

  2015cited by this paper
• A Review of Gene Therapy in Canine and Feline Models of Lysosomal Storage Disorders

  2015cited by this paper
• Gene therapy returns to centre stage

  2015cited by this paper
• Risks of Insertional Mutagenesis by DNA Transposons in Cancer Gene Therapy

  2015cited by this paper
• Haemophilia gene therapy: Progress and challenges.

  2015cited by this paper
• Hepatocyte Transfection in Small Pigs After Weaning by Hydrodynamic Intraportal Injection of Naked DNA/Minicircle Vectors

  2015cited by this paper
• Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.

  2015cited by this paper
• Liver-directed lentiviral gene therapy in a dog model of hemophilia B

  2015cited by this paper
• Hydrodynamic delivery.

  2015cited by this paper
• Mucopolysaccharidosis type VII: A powerful experimental system and therapeutic challenge.

  2014cited by this paper
• A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19

  2014cited by this paper
• Cellular Immune Response Against Firefly Luciferase After Sleeping Beauty–Mediated Gene Transfer In Vivo

  2014cited by this paper
• Mucopolysaccharidosis type I.

  2014cited by this paper
• Development of gene transfer for induction of antigen-specific tolerance

  2014cited by this paper
• Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

  2014influential reference
• Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits

  2013cited by this paper
• Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy.

  2013cited by this paper
• Quantitative Analysis of α-L-Iduronidase Expression in Immunocompetent Mice Treated with the Sleeping Beauty Transposon System

  2013cited by this paper
• Novel electric power-driven hydrodynamic injection system for gene delivery: safety and efficacy of human factor IX delivery in rats

  2013cited by this paper
• The de ritis ratio: the test of time.

  2013cited by this paper
• The effect of neonatal gene therapy with a gamma retroviral vector on cardiac valve disease in mucopolysaccharidosis VII dogs after a decade.

  2013cited by this paper
• Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.

  2012cited by this paper
• Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies.

  2011cited by this paper
• Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning

  2011cited by this paper
• The Sleeping Beauty transposon system: a non-viral vector for gene therapy.

  2011cited by this paper
• Hemophilia gene therapy: a Holy Grail found.

  2011cited by this paper
• Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression.

  2010cited by this paper
• Translating Sleeping Beauty transposition into cellular therapies: Victories and challenges

  2010cited by this paper
• A transposon and transposase system for human application.

  2010cited by this paper
• Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B.

  2010cited by this paper
• Different Serum Enzyme Levels Are Required to Rescue the Various Systemic Features of the Mucopolysaccharidoses

  2010cited by this paper
• Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery.

  2010cited by this paper
• Strategies to modulate immune responses: a new frontier for gene therapy.

  2009cited by this paper
• Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system.

  2009cited by this paper
• Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates

  2009influential reference
• Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.

  2008cited by this paper
• Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.

  2007cited by this paper
• Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.

  2007cited by this paper
• Gene therapy for mucopolysaccharidosis

  2007cited by this paper
• Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon‐mediated gene delivery: implications for non‐viral gene therapy of mucopolysaccharidoses

  2007cited by this paper
• Role of Kupffer cells in the pathogenesis of liver disease.

  2006cited by this paper
• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

  2006cited by this paper
• Structure-based prediction of insertion-site preferences of transposons into chromosomes

  2006cited by this paper
• Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.

  2005cited by this paper
• Liver enzyme alteration: a guide for clinicians

  2005cited by this paper
• Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs.

  2004cited by this paper
• Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice.

  2004cited by this paper
• Gene transfer into genomes of human cells by the sleeping beauty transposon system.

  2003cited by this paper
• Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo.

  2003cited by this paper
• Structure-function analysis of the inverted terminal repeats of the sleeping beauty transposon.

  2002cited by this paper
• Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy.

  2002cited by this paper
• Absence of Circulating Factor IX Antigen in Hemophilia B Dogs of the UNC-Chapel Hill Colony

  2000cited by this paper
• Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system

  2000cited by this paper
• High Levels of Foreign Gene Expression in Hepatocytes after Tail Vein Injections of Naked Plasmid DNA

  1999cited by this paper
• Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA

  1999cited by this paper
• Molecular diagnostic tests for ascertainment of genotype at the mucopolysaccharidosis type VII locus in dogs.

  1998cited by this paper
• Follow-up of nine patients with Hurler syndrome after bone marrow transplantation.

  1998cited by this paper
• Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells.

  1997cited by this paper
• Protocols for gene transfer in neuroscience : towards gene therapy of neurological disorders

  1996cited by this paper
• Long-term outcome of Hurler syndrome following bone marrow transplantation.

  1993cited by this paper
• Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I.

  1992cited by this paper
• Heterogeneity of rat liver and spleen macrophages in gadolinium chloride–induced elimination and repopulation

  1992cited by this paper
• β-Glucuronidase Deficiency in a Dog: a Model of Human Mucopolysaccharidosis VII

  1984cited by this paper
• Canine alpha-L-iduronidase deficiency. A model of mucopolysaccharidosis I.

  1982cited by this paper
• Helper-independent Sleeping Beauty Transposon–transposase Vectors for Efficient Nonviral Gene Delivery and Persistent Gene Expression in Vivo

  year unknowncited by this paper

• Mucopolysaccharidoses—What Clinicians Need to Know: A Clinical, Biochemical, and Molecular Overview

  2025cites this paper
• Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy

  2024cites this paper
• Early Subcellular Hepatocellular Alterations in Mice Post Hydrodynamic Transfection: An Explorative Study

  2023cites this paper
• Role of Transposable Elements in Genome Stability: Implications for Health and Disease

  2022cites this paper
• Clinical Development of Cell Therapies to Halt Lysosomal Storage Diseases: Results and Lessons Learned.

  2021cites this paper
• Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement

  2021cites this paper
• Lysosomal storage diseases

  2018cites this paper
• Preclinical and clinical advances in transposon-based gene therapy

  2017cites this paper
• Sleeping Beauty Awakens New Interest

  2017cites this paper
• Transposons: Moving Forward from Preclinical Studies to Clinical Trials

  2017influential citation